Irradiation and bevacizumab in high-grade glioma retreatment settings.
Niyazi
Maximilian
M
Department of Radiation Oncology, Ludwig-Maximilians-University Munich, Munich, Germany.
Ganswindt
Ute
U
Schwarz
Silke Birgit
SB
Kreth
Friedrich-Wilhelm
FW
Tonn
Jörg-Christian
JC
Geisler
Julia
J
la Fougère
Christian
C
Ertl
Lorenz
L
Linn
Jennifer
J
Siefert
Axel
A
Belka
Claus
C
D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000098:blood supply / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy / Q000379:methods*; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005240:Feasibility Studies; D005260:Female; D005910:Glioma / Q000098:blood supply / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000098:blood supply / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011879:Radiotherapy Dosage; D019233:Retreatment / Q000379:methods; D012189:Retrospective Studies; D016019:Survival Analysis; D000077204:Temozolomide; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D055815:Young Adult
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D018906:Antineoplastic Agents, Alkylating; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D003606:Dacarbazine; D000077204:Temozolomide